ABILIFY ASIMTUFII Drug Patent Profile

Which patents cover Abilify Asimtufii, and what generic alternatives are available?

Abilify Asimtufii is a drug marketed by Otsuka and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-four patent family members in thirty-one countries.

The generic ingredient in ABILIFY ASIMTUFII is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Asimtufii

A generic version of ABILIFY ASIMTUFII was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY ASIMTUFII

International Patents:	74
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for ABILIFY ASIMTUFII
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY ASIMTUFII
What excipients (inactive ingredients) are in ABILIFY ASIMTUFII?	ABILIFY ASIMTUFII excipients list
DailyMed Link:	ABILIFY ASIMTUFII at DailyMed

See drug prices for ABILIFY ASIMTUFII

Pharmacology for ABILIFY ASIMTUFII

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for ABILIFY ASIMTUFII

ABILIFY ASIMTUFII is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes			Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes			Y

Expired US Patents for ABILIFY ASIMTUFII

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023

EU/EMA Drug Approvals for ABILIFY ASIMTUFII

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
Zentiva, k.s.	Aripiprazole Zentiva	aripiprazole	EMEA/H/C/003899Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-25
Sandoz GmbH	Aripiprazole Sandoz	aripiprazole	EMEA/H/C/004008Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-08-20

International Patents for ABILIFY ASIMTUFII

See the table below for patents covering ABILIFY ASIMTUFII around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	12014502379	INJECTABLE PREPARATION
World Intellectual Property Organization (WIPO)	03026659
South Korea	20150003861
Jordan	P20200109
Hungary	E045979
China	101792415
Poland	393603

Supplementary Protection Certificates for ABILIFY ASIMTUFII

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119

Abilify Asimtufii (aripiprazole lauroxil) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

Abilify Asimtufii (aripiprazole lauroxil; extended-release injectable) is an add-on, quarterly aripiprazole option designed to capture share from monthly branded and off-cycle maintenance regimens in schizophrenia and related indications where long-acting injectables (LAIs) reduce adherence gaps. The financial trajectory is shaped by (1) launch-stage uptake into specialist prescribing channels, (2) class and molecule-level substitution among LAIs, (3) payer steering via formulary tiering and preferred access, and (4) the cadence mismatch versus monthly LAIs that favors patient persistence and clinic scheduling economics.

What is the product’s commercial starting point and launch-driven demand profile?

Asimtufii is the branded, quarterly formulation of aripiprazole lauroxil. Commercial performance typically follows a three-phase path for LAIs: initial conversion of existing LAI users, incremental start-capture among maintenance patients who seek less frequent dosing, then expansion through payer coverage stabilization.

Key demand drivers for quarterly LAIs in routine care:

• Adherence and persistence: Less frequent dosing reduces missed appointments and discontinuation risk.
• Clinic throughput: A quarterly schedule concentrates administration into fewer visits, often aligning with clinic billing cadence.
• Switchability: Uptake accelerates when payers and clinicians treat the product as a continuation option for aripiprazole-treated patients or as a migration path from other LAIs.

While product-specific revenue totals are not provided here, the market structure is clear: quarterly LAIs compete directly on schedule convenience and on the payer’s willingness to prefer higher WAC products when reduced visit frequency offsets plan administration costs.

How does Asimtufii’s market positioning shape uptake versus competing LAIs?

Competitive set and substitution mechanics

Asimtufii competes within the LAI schizophrenia maintenance segment and, in practice, competes with both:

• Monthly LAIs (more granular dosing access, often entrenched via long-standing formulary preference)
• Other atypical LAI options with different dosing schedules and access conditions

Market substitution is driven by:

• Plan “preferred” status (often locked to contracting and rebates)
• Injection visit economics (clinic workflow and patient scheduling)
• Treatment history (patients already stabilized on an LAI tend to switch only when clinically justified or when access changes)

Quarterly dosing is the differentiation lever

A quarterly product is structurally advantaged when payers and providers can quantify fewer administrations. That advantage tends to translate into:

• Higher conversion of stable patients who want fewer visits
• Lower churn when patients see the product as “set and forget” within a maintenance plan
• Slower but more durable share gains as adherence and persistence compound

The risk is that quarterly formulations can face inertia if plans already cover a monthly LAI with minimal prior authorization friction. Uptake therefore often depends on payer negotiations and policy harmonization across lines of business.

What payer and channel dynamics determine financial trajectory?

1) Formulary access and prior authorization

LAI adoption is usually a function of:

• Preferred tier placement (or equivalent rebate-backed access)
• Prior authorization triggers (diagnosis confirmation, failure of oral therapy, step edits from other LAIs)
• Quantity or duration controls (common with high-cost injectables)

Financial trajectory sensitivity:

• Fast share gains when coverage is broad and PA requirements are limited.
• Delayed revenue ramp when coverage is restricted to narrow patient subgroups.

2) Contracting, rebates, and net price

Net revenue path depends more on contracting than list price for LAIs. Quarterly dosing can influence contracting because:

• Lower administration frequency can change payer cost-of-care assumptions.
• Rebates are used to secure preferred placement, offset list price differentials, and control switching behavior.

3) Specialty channel conversion

LAIs are typically managed through a blend of:

• Behavioral health and psychiatry clinics
• Community mental health services
• Hospital outpatient injection programs

In that environment, revenue trajectory tracks:

• Time-to-adoption in prescriber cohorts
• Acquisition of clinic buy-in for storage, administration, and patient scheduling
• Nursing and administration capacity

How will Asimtufii’s financial trajectory likely evolve against its lifecycle stage?

A quarterly LAI’s revenue pattern commonly follows:

• Year 1-2 ramp: Build penetration in established LAI cohorts and incremental starts from oral or less convenient regimens.
• Year 2-3 normalization: Expand within covered populations, with share gains driven by switching after coverage rules stabilize.
• Year 3+: maturation: Growth depends on persistence and new-patient starts, net of competitive pressure and formulary churn.

For Asimtufii, the monetization equation is:

• Revenue equals (covered population) x (share of LAI prescriptions) x (dose frequency and persistence) x (net price after rebates)
• Quarterly dosing can raise persistence and reduce discontinuations, supporting the persistence term once adoption is established.

What are the key market risks to upside and the structural headwinds?

Upside risks (accelerants)

• Faster than expected payer preference for quarterly LAIs.
• Switching programs that encourage movement from monthly LAIs.
• Improved persistence in real-world settings due to reduced visit burden.

Downside risks (constraints)

• Formulary entrenchment of monthly LAIs through preferred status and established clinic processes.
• Prior authorization complexity that slows conversion.
• Budget impact scrutiny where plans challenge high-cost injectables even when visit frequency is lower.
• Competitive launch or repositioning within LAI schizophrenia where newer products gain exclusivity and rebate leverage.

How do product label scope and administration specifics influence adoption economics?

LAI uptake is operational. Clinicians need predictable administration schedules, and clinics must integrate product-specific workflows. Quarterly dosing generally:

• Reduces administration burden compared with monthly products
• Increases the operational value of patient retention in an injection cadence

From a business standpoint, adoption depends on:

• Smooth scheduling and clinic capacity planning for quarterly administration cycles
• Patient persistence that stabilizes expected administration volumes
• Lower injection “churn” when patients discontinue other regimens

What investment and R&D signals matter for financial outcomes?

Even for an already marketed LAI, the financial trajectory is tied to forward-looking signals:

• Ongoing lifecycle expansion: new indications or expanded patient eligibility can widen addressable demand.
• Formulary strategy: contracting posture determines net price and preferred access durability.
• Manufacturing and supply reliability: LAI stock-outs directly hit administered volumes and can damage prescriber trust and persistence.

For R&D portfolios, the key implication is that quarterly dosing creates a practical barrier to switching. That barrier tends to increase the value of maintenance franchise assets versus episodic therapies.

Competitive and pricing context: what determines the net revenue outcome?

Net revenue is a function of:

• WAC to net price conversion through rebates and discounts
• Volume and mix, including whether the product is used as:
  • A preferred first-line LAI switch
  • A secondary option after other LAIs fail access or tolerability
• Persistence-based scaling, where quarterly schedules can improve the total administered dose over maintenance horizon

LAI markets are structurally rebate-driven. In practice, a quarter-dose can produce net outcomes that are more stable when:

• Plans accept higher upfront drug cost in exchange for lower administration frequency
• Clinician switching behavior is aligned with plan contracting incentives

Key financial trajectory expectations (scenario framing tied to mechanics)

Base-case path

• Moderate initial conversion from existing LAI patients
• Expansion as payer coverage broadens
• Revenue growth supports persistence, with competitive share gains limited by monthly LAI entrenchment

Upside path

• Rapid payer preference secured through contracting
• Switch-through programs and simplified access
• Faster persistence gains in quarterly cohorts

Downside path

• Slow formulary access and PA friction
• Entrenched monthly LAI preferred status reduces switch velocity
• Competitive rebate pressure compresses net price

Bottom-line business view

Asimtufii’s market dynamics are driven by the quarterly LAI advantage, but financial performance is determined by net access and persistence rather than list price. Revenue trajectory should track (1) payer preference build-out, (2) switch rates from existing LAIs, and (3) administered dose persistence.

Key Takeaways

• Asimtufii competes within schizophrenia LAI maintenance on schedule convenience (quarterly vs monthly), which supports persistence if payer access is stable.
• Financial trajectory is governed by formulary positioning, prior authorization friction, and rebate-driven net price conversion.
• The most material upside lever is faster preferred access and patient switching into quarterly dosing; the most material headwind is entrenched monthly LAI preference and administrative barriers.
• Growth should mature through persistence-based dose continuity rather than episodic demand.

FAQs

1. What drives Asimtufii adoption in the real-world market?
   Payer coverage stability, prescriber switching behavior from existing LAIs, and clinic scheduling economics that favor fewer administrations.

2. How does quarterly dosing change the economics versus monthly LAIs?
   It reduces administration frequency, which can improve persistence and lower administration burden, affecting payer cost-of-care assumptions and contracting terms.

3. What matters more for revenue than list price?
   Net price after rebates and discounts, which is tightly linked to formulary tier placement and preferred access contracting.

4. What is the primary risk to share growth?
   Prior authorization and formulary entrenchment of preferred monthly LAIs that slow switching velocity and compress net price.

5. How does persistence affect financial outcomes for LAIs?
   Persistence increases the number of administered doses across the maintenance horizon, which supports revenue scaling once patients are stabilized on the quarterly cadence.

References

[1] U.S. Food and Drug Administration. “Abilify Asimtufii (aripiprazole lauroxil) Prescribing Information.” FDA label.